Novartis AG and Amgen Inc. announced on 11 July that they have discontinued two Phase II/III clinical trials for CNP520 (umibecestat), a beta-site amyloid precursor protein-cleaving enzyme (BACE) inhibitor, in the prevention or delayed onset of Alzheimer's disease. The development makes Eisai Co. Ltd./Biogen's elenbecestat the only BACE inhibitor left in clinical testing for Alzheimer's disease after numerous prior failures for the class.
[Sidebar#SC099808]







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)